MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2022 | $900,000 | Replaced |
| 1st Quarter - Amendment | Apr 20, 2022 | $890,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| DAMON SHELBY PORTER | — |
| PETER SLONE | — |
Medicare/Medicaid MMM
General Medicare/Medicaid Issues,; Prescription Drug Price Reform. Transparency Requirements. Strategic National Stockpile. COVID-19 Response. Drug pricing and transparency, access and adherence H.R.3 and H.R.19,; The Improving Seniors' Timely Access to Care Act H.R.3173,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,;The Safe Step Act H.R.2163 and S.464.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| THOMAS BORCK | — |
| BEN JONES | — |
| LISA LANGENDERFER | — |
| DAMON SHELBY PORTER | — |
| PETER SLONE New | — |
Pharmacy PHA
Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,; Drug pricing and transparency, access and adherence H.R.3 and H.R.19
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| THOMAS BORCK | — |
| BEN JONES | — |
| LISA LANGENDERFER | — |
| DAMON SHELBY PORTER | — |
Taxation/Internal Revenue Code TAX
Drug pricing and transparency, access and adherence H.R.3 and H.R.19.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| DAMON SHELBY PORTER | — |
Tariff (miscellaneous tariff bills) TAR
Social determinants of health; health disparities in underserved communities; chronic health conditions H.R.2503,; Drug pricing and transparency, access and adherence,; Domestic sourcing and production,; COVID relief and pandemic response, pandemic preparedness; Supply chain, global operations, trade.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| DAMON SHELBY PORTER | — |
| PETER SLONE New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.